Physician profile
Henry Fox
NPI 1396810578
$20,959.62
in general payments reported to CMS, 2019-2025
60 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,322 · 2020: $991 · 2021: $2,889 · 2022: $5,203 · 2023: $2,123 · 2024: $1,253 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $5,584.23 | 2019-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $3,992.77 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $3,568.69 | 2019-2025 | Calquence, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $1,133.85 | 2019-2025 | Vpriv |
| Beigene USA, INC. | $716.71 | 2020-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $417.28 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $361.83 | 2019-2025 | Reblozyl, Breyanzi, Eliquis |
| Celgene Corporation | $343.43 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Rigel Pharmaceuticals, INC. | $321.45 | 2019-2022 | |
| Genzyme Corporation | $317.24 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $259.50 | 2019-2023 | Imbruvica |
| Amgen INC. | $246.98 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Bayer Healthcare Pharmaceuticals INC. | $203.31 | 2019-2023 | |
| Daiichi Sankyo INC. | $201.03 | 2019-2025 | Datroway |
| Pfizer INC. | $200.52 | 2019-2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.